PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2424082

[Immunization plan for foreign travel and sojourn].

C Herzog
View original source ↗Export metadata ↓

Abstract

Immunization offers the traveller protection against dangerous communicable diseases. In recent years the international traveller has had to consider not only the vaccinations required by some countries under the International Health Regulations (at present only yellow fever and cholera) but also a growing number of vaccinations for individual protection. The risk of infection varies with destination, means of travel, lifestyle, season and length of stay abroad, and the vaccination schedule and counselling must be adapted accordingly. Apart from the "exotic" vaccinations mentioned above, a short review is presented of the indications, use and efficacy of vaccinations against poliomyelitis, tetanus, diphtheria, hepatitis B (+ hepatitis A prophylaxis), typhoid, meningococci, rabies, tuberculosis and tick-borne encephalitis.

Explore related subjects

Cholera VaccinesDiphtheria ToxoidHepatitis AHumansImmunizationImmunization ScheduleImmunization, SecondaryMalariaPoliovirus Vaccine, OralRiskSwitzerlandTetanus ToxoidTravelTropical ClimateTyphoid-Paratyphoid VaccinesWorld Health OrganizationYellow Fevergamma-GlobulinsEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Herzog. 1986-05-17. [Immunization plan for foreign travel and sojourn].. https://pubmed.ncbi.nlm.nih.gov/2424082/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Induction of interleukin-8 in T84 cells by Vibrio cholerae.

The induction of interleukin-8 (IL-8) in vitro has been suggested to correlate with the reactogenicity of Vibrio cholerae vaccine candidates. V. cholerae vaccine candidate 638, a hemagglutinin protease/hap-defective strain, was recently reported to be well tolerated in human volunteers, suggesting a role for Hap in reactogenicity. We examined the role of hap in the induction of IL-8 in intestinal epithelial T84 cells. Wild-type V. cholerae strains 3038 and C7258 and a vaccine candidate strain, JBK70, induced levels of IL-8 similar to those of their isogenic hap mutants. Supernatant containing Hap did not stimulate IL-8 production at a variety of concentrations tested, suggesting that Hap itself does not induce IL-8 production. Furthermore, supernatant from CVD115, which had deletions of hap and rtxA (encoding repeats in toxin) and was derived from a reactogenic strain, CVD110, induced IL-8 production in T84 cells in a dose-dependent manner. The IL-8-stimulating activity of CVD115 culture supernatants was growth phase dependent and was strongest in stationary phase cultures. This IL-8 stimulator(s) was resistant to heat treatment but sensitive to proteinase. Protease activity in vitro did not correlate with the reactogenicity of V. cholerae vaccine candidates. Our data suggest that Hap is not an IL-8 inducer in T84 cells and that the IL-8 stimulator in the supernatant of V. cholerae culture may play a role in reactogenicity.

Cholera Vaccines↗
PubMed2002

Sample size determination for phase II studies of new vaccines.

Prior to the evaluation of protective efficacy, experimental vaccines conventionally undergo phase II randomized controlled clinical trials to evaluate safety and immunogenicity. Typically, an experimental vaccine is compared to another vaccine or to a placebo with respect to adverse events or immune responses, or both. Various strategies and methods are available for design and analysis of such studies. A key aspect of design is the determination of sample size. Often a sample size is chosen that gives a high probability ("power") of finding a statistically significant difference in an outcome of interest, if a difference of a specified size exists. This approach is appropriate when the primary goal of the study is to demonstrate that a difference exists between two groups or treatments. It may not, however, give adequate assurance that a confidence interval around the observed difference will be narrow enough to exclude the possibility of an unacceptably low immune response or unacceptably high adverse event frequency in recipients of the experimental vaccine. In this paper, we apply the "non-inferiority" trial design to phase II vaccine studies; that is, we design the trial to rule out a difference between the vaccine and control in immunogenicity or reactogenicity that is considered unacceptable. We also consider a setting in which the desire is to show that the difference between immune response rates for vaccine and control is greater than a specified value.

Cholera Vaccines↗